

Regional Office for the Eastern Mediterranean

Weekly Epidemiological Monitor

ISSN 2224-4220

Volume 9 Issue 12; 20 March 2016

Current major event

Recommended Seasonal Influenza Vaccine for use in 2016-17

In February 2016, WHO has recommended influenza viruses for inclusion in the seasonal influenza vaccines for the countries of northern hemisphere for 2016-17.

These recommendations are based on the antigenic and genetic analysis of the circulating seasonal influenza viruses shared by the countries with WHO through the Global Influenza Surveillance and Response System (GISRS).


Editorial note

Immunization against influenza is considered to be an essential public health intervention to control both seasonal epidemic and pandemic influenza.

The WHO's recommendations provide guidance for the countries and the vaccine manufacturers on the seasonal influenza virus to be included in the human influenza vaccines against seasonal influenza during the winter. The regulatory agencies make the final decision about which influenza strains may be used in influenza vaccine to be licensed in their country. In contrast to many other vaccines, influenza vaccines strains are updated frequently to contain representative circulating viruses as human influenza virus evolve continuously.

Usually, seasonal influenza vaccine comprise of three different virus types (i.e., are trivalent) and include influenza A (H1N1), A (H3N2) and influenza B viruses. In the period between September 2015 and March 2016, influenza virus circulation was active in the countries of the Eastern Mediterranean Region (Please see above). During this period, the influenza A(H1N1)pdm09 virus was predominant in many countries and co-circulated with influenza A(H3N2). Influenza B virus was also circulating in some countries like Egypt, Morocco and Tunisia.

During last winter season, a number of countries in the Region experienced a surge of seasonal influenza cases which was predominantly caused by influenza A (H1N1)pdm09 virus. These countries included Islamic Republic of Iran, JorNumber of specimens positive for influenza by subtype



A (Not subtyped) ____ A(H1) B (Lineage not determined) B (Victoria lineage) A(H3) B (Yamagata lineage)

Recommended influenza virus to be included in the 2016-17 seasonal influenza vaccine for northern hemisphere Trivalent vaccine:

- an A/California/7/2009 (H1N1)pdm09 -like virus;
- an A/Hong Kong/4801/2014 (H3N2)like virus;
- a B/Brisbane/60/2008-like virus.

Quadrivalent vaccine

- The above three viruses and
- a B/Phuket/3073/2013-like virus.

dan, occupied Palestine territory (oPt), Pakistan and Syria. In addition, influenza A (H3N2) was predominant most of the winter season in Yemen causing a similar surge of seasonal influenza cases.

With the enhancement of surveillance system for severe acute respiratory infection (SARI) in the Region, the detection of seasonal influenza cases has increased substantially over the last few years. An increasing body of knowledge has also been generated through these systems on the patterns of circulating seasonal influenza virus as well as the seasonality and risk factors of the influenza-associated illnesses that require hospitalizations.

The countries, in the Region, can now use the available body of evidence on the epidemiology of influenza to introduce seasonal influenza vaccines as part of its control strategy to prevent seasonal surge. Introducing the vaccines for seasonal influenza targeting the highest risk age groups can minimize morbidity and mortality attributed to influenza.

Update on outbreaks

in the Eastern Mediterranean Region

MERS-CoV in Saudi Arabia; Undiagnosed viral haemorrhgaic fever in Sudan

Current public health events of international concern

[cumulative N° of cases (deaths), CFR %]

.... I........ . 2007 2017

MERS-CoV: 2012-2016

Avian innuenza: 2000-2010		
Egypt (A/H5N1)	[346 (117), 33.8%]	
Egypt (A/H9N2)	[3 (0)]	

Saudi Arabia [1277 (549), 42.9%] Jordan [39 (12), 31%] Oman [7 (3), 42.8%] UAE [78 (11), 14.1%] Kuwait [3 (1), 33.3%] Republic of Korea [186 (36), 19.3%] Oatar [14 (5), 35%]

[6 (2), 33.3%]			
Ebola Virus Disease: 2014-2016			
[3804 (2536),66.6%]			
[10675 (4809),45%]			
[14124 (3956),28%]			
Viral Haemorrhagic Fever (of unknown aetiology)			

[561 (101),26.3%]

wild pollovii us. 2014-2016	D .
Pakistan	[367 (0)]
Afghanistan	[50(0)]
Lassa fever: 2015-2016	

[159(82), 51.5%) Nigeria Benin [71(23),32.3%